PGR progesterone receptor
ENSG00000082175 · protein coding · Open Targets profile
The steroid hormones and their receptors are involved in the regulation of eukaryotic gene expression and affect cellular proliferation and differentiation in target tissues. Depending on the isoform, progesterone receptor functions as a transcriptional activator or repressor. {ECO:0000269|PubMed:10757795, ECO:0000269|PubMed:1587864, ECO:0000269|PubMed:37478846, ECO:0000269|PubMed:9407067, ECO:0000305}.
Each band is a group of drugs. It runs from the kind of drug on the left to the furthest stage that drug has reached in any disease on the right. Thicker bands mean more drugs.
Approved bands are highlighted. Withdrawn means the drug was pulled from the market or from development. A combined phase counts as the later one (Phase 1/2 is shown as Phase 2). Hover a band for the drug names. Source: Open Targets Platform, fetched live.
Each row is a cancer, strongest overall evidence first. The two dots show how strong the inherited (germline) and tumour-mutation (somatic) evidence is; the line between them is the gap.
Scores run from 0 (no evidence) to 1 (strongest). A missing dot at 0 means Open Targets holds no evidence of that kind. Source: Open Targets Platform, fetched live.
Tractability
- Small molecule
- Approved Drug, Structure with Ligand, High-Quality Ligand, High-Quality Pocket, Druggable Family
- Antibody
- GO CC high conf
- PROTAC
- UniProt Ubiquitination, Database Ubiquitination, Small Molecule Binder
gnomAD loss of function constraint: o/e 0.32846999168395996 (upper bound 0.45875999331474304). Low values mean loss of function is poorly tolerated, a safety flag for inhibition.
Who runs trials of these drugs
Principal investigators and study chairs on 232 registry trials, updated in the last three years, of the most advanced drugs against PGR (norgestrel, ethynodiol, segesterone, nomegestrol, danazol, mifepristone, trimegestone, levonorgestrel, norgestimate, norethindrone, norelgestromin, desogestrel), ranked by Phase 2+ trials. Live from ClinicalTrials.gov.
- Diana BlitheNICHD Director · 3 of 4 trials Phase 2+
- David TurokUniversity of Utah · 3 of 3 trials Phase 2+
- Andrea OlariuCOO · 2 of 2 trials Phase 2+
- Andrea R HagemannWashington University School of Medicine · 2 of 2 trials Phase 2+
- Rita NandaUniversity of Chicago · 2 of 2 trials Phase 2+
- Sandeep JagtapMeda Pharma GmbH & Co. KG (a Viatris company) · 2 of 2 trials Phase 2+
- Shannon N WestinM.D. Anderson Cancer Center · 2 of 2 trials Phase 2+
- Takefumi MatuoHyogo Prefectural AWAJI Hospital · 2 of 2 trials Phase 2+
- Aaron M LazorwitzYale University · 1 of 1 trials Phase 2+
- ALISON EDELMANOregon Health and Science University · 1 of 1 trials Phase 2+
- Amy DiVastaBoston Children's Hospital · 1 of 1 trials Phase 2+
- André Luiz M OliveiraScience Valley Research Institute · 1 of 1 trials Phase 2+
- Andrea LukesCarolina Woman's Research and Wellness Center · 1 of 1 trials Phase 2+
- Andreas ObermairQueensland Centre for Gynaecological Cancer · 1 of 1 trials Phase 2+
- Andrew M NovickUniversity of Colorado Denver Anschutz Medical Campus · 1 of 1 trials Phase 2+
Registry trials of norgestrel, ethynodiol, segesterone, nomegestrol, danazol, mifepristone, trimegestone, levonorgestrel, norgestimate, norethindrone, norelgestromin, desogestrel updated in the last three years, counted by the country group of their listed sites. A trial with sites in several groups counts in each; 188 of 209 have all sites in one country.
Site counts are not patients per country, and trials registered only outside ClinicalTrials.gov are not covered. Where sites are is a fact about the record, not a judgement of its quality. Europe is the EU and EEA, the UK and Switzerland. 23 trials list no sites and are left out. Source: ClinicalTrials.gov, fetched live.
118 trials of drugs against PGR were stopped early; 23 give no reason
Terminated, withdrawn and suspended interventional trials of norgestrel, ethynodiol, segesterone, nomegestrol, danazol, mifepristone, trimegestone, levonorgestrel, norgestimate, norethindrone, norelgestromin, desogestrel, newest update first, live from ClinicalTrials.gov. Each reason is quoted exactly as the registry gives it; we do not sort reasons into safety, efficacy or business. Dates are the last registry update. Showing the 25 most recent of 118.
- terminated · 2026-10-27 · National Heart, Lung, and Blood Institute (NHLBI) · Danazol“Study was stopped due to poor accrual”
- withdrawn · 2026-09-16 · University Hospital, Basel, Switzerland · matched by the registry's drug synonyms“The study was withdrawn before initiation. Reasons: no ethics approval obtained and anticipated roll-out of lenacapavir”
- withdrawn · 2026-07-30 · Bayer · matched by the registry's drug synonyms“Bayer cancelled study 22923 due to enrollment challenges, including difficulties identifying eligible patients, participation requirements, and site burden. The decision was unrelated to safety and does not change Mirena's benefit-risk profile.”
- withdrawn · 2026-06-05 · University of Chicago · matched by the registry's drug synonyms“Data not collected and analyzed; withdrawn due to lack of bandwidth.”
- withdrawn · 2026-02-23 · University of Virginia · matched by the registry's drug synonyms“No funding, time, or personnel to complete this study.”
- withdrawn · 2026-01-12 · Washington University School of Medicine · matched by the registry's drug synonyms“Low accrual”
- terminated · 2025-12-23 · University of Chicago · Mifepristone“side effects (rash)”
- terminated · 2025-11-21 · Organon and Co · matched by the registry's drug synonyms“Sponsor decision to stop the study early and complete all required study close-out activities. This decision was made for business reasons unrelated to safety. None of the pre-specified efficacy endpoints were analyzed.”
- terminated · 2025-11-20 · Kimberly Myer · Levonorgestrel“We weren't seeing as many pregnancies we initially thought.”
- withdrawn · 2025-08-28 · Endeavor Health · matched by the registry's drug synonyms“Could not obtain approval for the planned study with available funding”
- terminated · 2025-08-05 · The University of Queensland · Danazol“Data Safety Monitoring Board recommended cessation due to futility”
- withdrawn · 2025-07-20 · United States Naval Medical Center, Portsmouth · matched by the registry's drug synonyms“No recruitment occurred and the PI stopped the study”
- withdrawn · 2025-07-20 · United States Naval Medical Center, Portsmouth · matched by the registry's drug synonyms“No recruitment occurred and the PI stopped the study.”
- withdrawn · 2025-06-06 · University of Chicago · matched by the registry's drug synonyms“Study has not received IRB approval.”
- terminated · 2025-04-04 · Milton S. Hershey Medical Center · Norethindrone Acetate“Recruitment has been challenging due to the BMI cutoff, need to take oral progesterone and abstain from cannabis products prior to the study.”
- withdrawn · 2025-03-21 · Boston Children's Hospital · norethindrone acetate (NETA)“No funding”
- withdrawn · 2024-11-14 · Sheba Medical Center · matched by the registry's drug synonyms“could not be funded”
- terminated · 2024-08-14 · Medicines360 · matched by the registry's drug synonyms“The data cutoff date of 05 April 2021 was chosen as it coincides with all subjects completing through Year 8 of use (intended duration of use for the product).”
- terminated · 2024-07-23 · Icahn School of Medicine at Mount Sinai · Danazol“low enrollment”
- terminated · 2024-06-20 · Organon and Co · matched by the registry's drug synonyms“Business reasons”
- terminated · 2024-05-17 · Organon and Co · matched by the registry's drug synonyms“Study terminated by Sponsor as a result of a business decision to discontinue the development program for MK-8342B for reasons unrelated to safety or efficacy.”
- terminated · 2024-02-02 · Baylor Research Institute · Norethindrone acetate (NTA)“It was in the best interest of the investigator to terminate the study earlier than anticipated.”
- terminated · 2023-11-18 · Children's Hospital Los Angeles · Desogestrel“Only one subject was studied, who did not respond.”
- terminated · 2023-07-25 · Gynuity Health Projects · Mifepristone + 2 doses of misoprostol 800 mcg“Enrollment”
- withdrawn · 2023-07-05 · Wake Forest University Health Sciences · Levonorgestrel Drug Implant“PI decision”
Paediatric incentives and obligations for PGR's drugs
For norgestrel, ethynodiol, segesterone, nomegestrol, danazol, mifepristone, trimegestone, levonorgestrel, norgestimate, norethindrone, norelgestromin, desogestrel: what EMA and FDA publish about paediatric plans, orphan status and pediatric approvals, and how many registered studies take children. Each line is a yes, no or not published fact from the record linked under it; none of it is a forecast.
- FDA pediatric target list: no · PGR is not on the listRule: Target is on FDA's Pediatric Molecular Target List (relevant targets). Source: FDA Pediatric Molecular Target List (Listed as February 2026 on the FDA Pediatric Oncology page; the file served is 9.7.22_the_relevant_molecular_target_list.xlsx, whose Summary of Changes sheet is headed 'SEPTEMBER 2022 UPDATE' (footnote date 2022-09-01)), 2026-11-11
- EU paediatric investigation plan: yes · EMA/PE/0000245149 (mifepristone;misoprostol, Treatment of termination of pregnancy): W: decision granting a waiver in all age groups for all conditions or indications, 12 Jun 2025; EMA/PE/0000240469 (levonorgestrel, Prevention of pregnancy): PM: decision on the application for modification of an agreed PIP, 16 May 2025; EMEA-002960-PIP02-21 (prasterone;levonorgestrel;ethinylestradiol, Treatment of hypoactive sexual desire disorder secondary to combined oral contraceptive use in women requiring contraception): W: decision granting a waiver in all age groups for all conditions or indications, 8 Sept 2021; EMEA-001437-PIP02-19 (mifepristone, Treatment of endometriosis): W: decision granting a waiver in all age groups for all conditions or indications, 14 Aug 2019; +9 moreRule: An EMA PIP decision (agreement, modification or waiver) lists the drug as its active substance, exact name. Source: EMA data download (dated snapshot), 2026-11-11
- EU orphan designation: yes · EU/3/11/925 positive 27 Oct 2011: Treatment of hypercortisolism (Cushing's syndrome) of endogenous origin; EU/3/05/298 withdrawn 27 Jul 2005: Treatment of Cushing's syndrome secondary to ectopic ACTH secretion; EU/3/09/614 positive 27 Feb 2009: Treatment of hypercortisolism (Cushing's syndrome) of endogenous originRule: An EU orphan designation lists the drug as its active substance (exact name) or belongs to a medicine that does; withdrawn and expired designations are listed with their status. Source: EMA data download (dated snapshot), 2026-11-11
- Authorised in the EU: yes · Evra: authorised since 22 Aug 2002; Zoely: authorised since 26 Jul 2011; Corluxin: application withdrawn, orphan medicine; Ioa: withdrawn since 16 Nov 2011Rule: An EMA medicine record lists the drug as its active substance or INN, exact name; national-only authorisations are not in this file. Source: EMA data download (dated snapshot), 2026-11-11
- FDA orphan designation: not published · FDA's orphan designation database turns away automated requests, so this app does not read it; search it by hand at the linkRule: Would be: an FDA orphan designation names the drug. Source: FDA orphan designations search
- FDA pediatric oncology approval: no · FDA's table lists no pediatric approval of norgestrel, ethynodiol, segesterone, nomegestrol, danazol, mifepristone, trimegestone, levonorgestrel, norgestimate, norethindrone, norelgestromin, desogestrelRule: FDA's Pediatric Oncology Drug Approvals table names the drug. Source: FDA Pediatric Oncology Drug Approvals (content current as of 2026-03-03), 2026-11-11
- Registered studies open to children: yes · 147 interventional studies of norgestrel, ethynodiol, segesterone, nomegestrol, danazol, mifepristone, trimegestone, levonorgestrel, norgestimate, norethindrone, norelgestromin, desogestrel include patients under 18; 17 are recruiting, not yet recruiting or activeRule: The registry's age group includes Child (birth to 17 years), which also counts studies that set no minimum age. Source: ClinicalTrials.gov search, 2026-11-11
Rare pediatric disease voucher. FDA, content current as of 29 Apr 2026: “As of February 3, 2026, enactment of the Consolidated Appropriations Act, 2026, the rare pediatric disease PRV program will sunset after September 30, 2029. FDA may not award any PRVs under this program after September 30, 2029.” Voucher sale prices are not shown here; they appear only as company-reported news. FDA: Rare Pediatric Disease Designation and Priority Review Voucher Programs
All 31 drugs and clinical candidates as a table
Each drug, stage and indication links to its Open Targets record, where the trials and approvals behind it are listed. Salt forms (for example a mesylate) are listed as Open Targets records them, as separate entries.